Modification of the MoAb structure via protein engineering to increase the binding affinity to the membranous form of the target antigens could significantly augment MM cell targeting, as reported for a novel anti-BCMA ADC [140] and anti-CD138 VIS832 [82]. Here, SDC1 is linked to Miyoshi myopathy.